Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00243802 · ClinicalTrials.gov registry record
Markers of Oxidative Stress Present in Left Atrial Appendage Tissue in Patients With Atrial Fibrillation
A clinical trial, sponsored by Emory University.
- Terminated
- Registry status
- 23
- Enrollment target
NCT00243802: Clinical Trial study, sponsored by Emory University.
NCT00243802 is a clinical trial that was terminated before completion, run by Emory University. The registered enrollment target is 23 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00243802 was terminated before completion, sponsored by Emory University.
- TERMINATED
- Registry status
- 23 participants
- Enrollment target
Study Summary
The purpose of the study is to look at the differences between people who have irregular heart beats coming from the upper chamber of the heart (atrial fibrillation) compared to those who do not have these irregular beats.
Primary Outcome
Increased oxidative stress and increased evidence of blood clotting.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2005-05 |
| Est. Completion | 2008-02 |
Why NCT00243802 stopped before completion
NCT00243802 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 23 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00243802 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00243802 about?
NCT00243802 is a clinical study titled "Markers of Oxidative Stress Present in Left Atrial Appendage Tissue in Patients With Atrial Fibrillation". The purpose of the study is to look at the differences between people who have irregular heart beats coming from the upper chamber of the heart (atrial fibrillation) compared to those who do not have these irregular beats.
What is the current status of trial NCT00243802?
This trial is currently terminated. The enrollment target is 23 participants. The study started on 2005-05. Estimated completion is 2008-02.
Who is sponsoring clinical trial NCT00243802?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia